Safety, Tolerability and Efficacy of MBS2320 in Patients With Rheumatoid Arthritis

Summary

Rheumatoid arthritis (RA) affects 1 percent of the population worldwide and up to 40 percent of patients don't respond to current treatments. MBS2320, the drug being tested in this trial, represents a new approach to treating RA, with the potential not only to reduce levels of inflammation but to also directly prevent bone damage.The aim of this project is to test the safety, tolerability and efficacy of MBS2320 in patients with RA in combination with an existing treatment, methotrexate.

Timeline

Start

2017-05-30

Primary completion

2018-11-16

Completion

2019-08-13

Drugs

Indications